PET/CT在原发性肺淋巴瘤诊断和疗效评估中的应用进展  

Application progress of PET/CT in the diagnosis and efficacy evaluation of primary pulmonary lymphoma

作　　者：柴源 张国建[2] Chai Yuan;Zhang Guojian(The First Clinical Medical College of Inner Mongolia Medical University,Hohhot 010050,China;Department of Nuclear Medicine,the Affiliated Hospital of Inner Mongolia Medical University,Hohhot 010050,China)

机构地区：[1]内蒙古医科大学第一临床医学院,呼和浩特010050 [2]内蒙古医科大学附属医院核医学科,呼和浩特010050

出　　处：《国际放射医学核医学杂志》2024年第9期571-575,共5页International Journal of Radiation Medicine and Nuclear Medicine

基　　金：内蒙古医科大学附属医院博士科研启动金(2022NYFYBS015);内蒙古医科大学致远人才(善学人才)项目(ZY0202037);内蒙古医科大学面上项目(YKD2021MS012);内蒙古自治区高校青年科技英才项目(NJYT22002)。

摘　　要：原发性肺内淋巴瘤(PPL)的发病率较低,且病理类型多,其影像表现也呈现多样化,因此临床上容易发生误诊.尽管穿刺活检被认为是诊断PPL的"金标准",但由于其属于有创性检查,部分患者可能无法接受.而PET/CT显像在CT形态学改变的基础上,进一步揭示了代谢、分子及受体分布等特征,从而显著提高了诊断的准确性.随着新型分子探针的涌现,PET/CT为PPL的诊断、疗效评估提供了一种无创性的、更为先进的检测手段.笔者就PET/CT在PPL诊断和疗效评估中的应用进展进行综述.Primary pulmonary lymphoma(PPL)is a disease associated with low incidence and multiple pathological types,as well as the diversity of its medical imaging characteristics,which is susceptible to clinical misdiagnosis.Although biopsy is the“gold standard”for the diagnosis of PPL,it may not be acceptable for some patients due to its invasive procedure.On the basis of the morphological changes of CT,PET/CT further revealed the metabolic,molecular and receptor distribution features,which significantly improved the diagnostic accuracy.With the emergence of new molecular probes,PET/CT provides a non-invasive and more advanced method for the diagnosis and evaluation of therapeutic efficacy of PPL.The authors review the application progress of PET/CT in the diagnosis and efficacy evaluation of primary pulmonary lymphoma.

关 键 词：正电子发射断层显像术 氟脱氧葡萄糖F18 体层摄影术 X线计算机 原发性肺内淋巴瘤 成纤维细胞活化蛋白抑制剂 

分 类 号：R730.44[医药卫生—肿瘤] R734.2[医药卫生—临床医学]